A929terms: aedes aegypt AND costs, dengue AND costs, chikungunya AND costs, zika AND costs e yellow fever AND costs) and completed with hand search on the reference list of included articles. Language was limited for English or Portuguese, and publication date for 2010-2017. We extracted data on government expenditures for the treatment of patients during the outbreaks of dengue, zika, chikungunya and yellow fever in those years. In the absence of data from Brazil, the search was expanded to Latin America. Official data from the Brazilian Ministry of Health (MoH) and the World Health Organization (WHO) were also reviewed. Results: we retrieved 423 articles, 410 were excluded due to duplicity, because they did not address our topic or Latin America and due to design inadequacies. Thirteen studies were included for analysis. Data from the literature estimated the cost of treating dengue at around R$ 1 billion per year. Treatment of microcephaly and Guillain-Barre syndrome, the most severe consequences of zika, was estimated at U$91,102. The economic impact of chikungunya treatment was projected at U$73.6 million. For the current outbreak of yellow fever, the economic impact has not yet been estimated. The Brazilian government has spent R$ 13.7 million to combat aedes aegypt according to official data from MoH since the outbreak of dengue in 2013. ConClusions: There is a need for greater investment in the prevention and control of the vector, which would save resources and avoid new outbreaks of these and other diseases transmitted by aedes aegypt.
and retrieved from an extra boost of ONCOVIEW database. ONCOVIEW is a continuous syndicated study on cancer treatment in the hospital setting, based on the collection of patient questionnaires. Patients inclusion criteria were the presence of an mCRC diagnosis, 3rd or later actual therapy line and no participation in a phase II or III clinical study. Information collected included patient demographic characteristics, mCRC characteristics (TNM Classification, Karnofsky performance status scale and mutation analyses) and treatments (actual and previous schedules, dosages and durations). Furthermore, an evaluation of the "Rechallenge" occurrence, in other words the use in 3rd or later line of treatment of drugs previously used, has been performed. Results: 261 patients diaries have been collected: 218 out of 261 patients were in third line of treatment, while 43 patients were in 4th or later treatment line. The most administered schema among third line patients was Capecitabine alone (63 patients), while the most used schema in fourth line was a combination of Fluorouracil and Folinic Acid (7 patients). About 40% of molecules administered in 3rd line and 67% of molecules administered in 4th line were used in previous lines. ConClusions: Results from the present study underline the unmet medical need in 3rd or later line of treatment of mCRC patients and the need for additional evidence-based treatment options.objeCtives: The objective of this study was to assess the oncologists' real clinical practice in the management of mCRC patients, with a focus on the 3rd, 4th and later lines of therapy in Italy. Methods: Data presented in this study were collected from medical records obtained by Italian oncologists on mCRC patients
A943 burden of AD in adults. We are conducting a transversal prospective study aiming to evaluate the global burden of AD. Methods: This is a cross-sectionnal study that is conducted since December 2016 and will last May 2017. We administrated a questionnaire to evaluate the impact of AD on daily life and included validated tools for the evaluation of disease burden (ABS-A), dermatology specific quality of life instrument (DLQI) and economic impact of AD. In addition, the severity of AD has also been evaluated by using a modified version of the PO-SCORAD. The questionnaires were mailed to adult patients belonging to the French support group for AD. In addition consecutive patients aged more than 18 and attending 4 French dermatology departments were asked to fill in these questionnaires after having obtained their oral consent. Results: We herein present the intermediate results of this study. Patients having answered were included in the present analysis. A total of 225 patients answered the questionnaires including 149 women and 76 men. Of the 225 patients, 108 declared moderate AD whereas 117 declared severe AD. One out of 4 patients had a disease that began during childhood whereas the aothers had an adult onset AD. In total, 71% of patients were followed-up by their dermatologist for their disease with significantly more patients with severe AD. Mean DLQI and ABS-A were respectively 19,6 (SD 5.7) and 47.6 (SD 15.2) in patients declaring severe AD and 13.7(SD 5.8) and 31.9(SD 14.1) in those declaring moderate AD. (p< 0,001). ConClusions: Our intermediate results showed that the burden of AD increase with the severity of AD and that AD impacts not only daily life but also professional activity and sexuality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.